Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: A method for operating an electric vehicle. The method includes receiving an information about an upcoming speed reduction (S1) and determining a release position or a release time at which a drive pedal of the electric vehicle is to be released, such that at a position corresponding to the speed reduction the electric vehicle travels at a speed corresponding to the speed reduction (S2). Moreover, a first notification position is determined for providing a first notification signal concerning the release of the drive pedal (S3). Alternatively or additionally a first notification time is determined for providing a first notification signal concerning the release of the drive pedal (S3). Furthermore, a data processing system is presented. including data processing means for carrying out the above method. Additionally, an electric vehicle including such a data processing system is explained. Also, a corresponding computer program product and a corresponding computer-readable medium are shown.

Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

Abstract: The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

Abstract: A computer-implemented method for cross-account model deployment is provided. According to the method, at least one artifact identifier of at least one to-be-deployed model artifact is provided. Further, at least one account tuple, the account tuple comprising a source account identifier identifying a source account and a target account identifier identifying a target account, is provided. Finally, the at least one to-be-deployed model artifact is moved from the source account to the target account. Further, a computer program element and a computer readable medium are provided.

Abstract: A pharmaceutical composition is provided which includes monoterpene derivatives such as perillyl alcohol conjugated with a therapeutic agent and further includes and an aliphatic tail such as a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: Disclosed herein are system, apparatus, article of manufacture, method and/or computer program product embodiments, and/or combinations and sub-combinations thereof, for dynamically enhancing the presentation of media content based on the detection of a trigger phrase during playing of the media content. An example embodiment operates by a media device receiving the trigger phrase from a user and generating a content enhancement protocol based on the trigger phrase and a user-supplied enhancement effect. During presentation of the media content, the media device may monitor content metadata associated with the media content to detect the trigger phrase, and upon detection, the media device may initiate the content enhancement protocol on the media content.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: A method for operating an electric vehicle. The method includes receiving an information about an upcoming speed reduction (S1) and determining a release position or a release time at which a drive pedal of the electric vehicle is to be released, such that at a position corresponding to the speed reduction the electric vehicle travels at a speed corresponding to the speed reduction (S2). Moreover, a first notification position is determined for providing a first notification signal concerning the release of the drive pedal (S3). Alternatively or additionally a first notification time is determined for providing a first notification signal concerning the release of the drive pedal (S3). Furthermore, a data processing system is presented. including data processing means for carrying out the above method. Additionally, an electric vehicle including such a data processing system is explained. Also, a corresponding computer program product and a corresponding computer-readable medium are shown.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Abstract: The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Abstract: Methods of improving reed performance are provided comprising the steps of treating one or more reeds with a solution and cycling the pressure over the solution from atmospheric pressure to reduced pressure to atmospheric pressure.

Abstract: A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Abstract: The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.

Abstract: The present disclosure relates to an analog of glucagon-like peptide-1 (glp-1) receptor agonist. The present disclosure provides analogs of glucagon-like peptide-1 (glp-1) receptor agonist wherein, the amino acid at position 2 of the glucagon-like peptide-1 (glp-1) receptor agonist is replaced with D-Alanine. The analogs of glucagon-like peptide-1 (glp-1) have one or more properties of prolonged half-life, better pharmacokinetic profile, retained biological activity, and being advantageous for relieving the patient's burden by reducing the dosing frequency and dose. The present disclosure further provides processes for preparing synthetic glucagon-like peptide-1 (glp-1) analogs.